Nolato NOLA B
Email when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
The news check keeps the assessment current.
General analysis — not personal advice.
Hold off on adding until the company demonstrates a steadier margin trend and clearer pricing impact; an existing position can be maintained if you accept higher near-term earnings risk.
Q3 results showed continued margin pressure and missed expectations, supporting keeping the case under review until margin trends stabilize.
Sentiment remains subdued after the report due to margin pressure and results below expectations.
NEUTRAL is the call. Negative is the market mood. Medium risk means some things can go wrong.
Latest change
- 30 Oct 2026 — Report showed margin pressure and missed expectations, driven by weaker auto volumes despite strong organic growth in Medical Solutions.
The full analysis is open. Follow the company free for the full change history — and email next time the picture changes.
Show all changes (6) — follow the company freeAbout the company
Nolato is a contract manufacturer developing and producing polymer-based components and systems (plastics, silicone, TPE) for medical/drug delivery and industrial customers. The company is profitable and in a mature phase, focusing on margin improvement and capacity expansion. A key growth driver is scaling pen/autoinjector components linked to diabetes and obesity therapies.
Bull case
Strong organic growth in Medical Solutions and contributions from acquisitions can support recovery once margins improve.
Bear case
Continued margin pressure from raw materials and weak automotive demand risks keeping profitability subdued and triggering negative estimate revisions.
Why this signal
Q3 results showed continued margin pressure and missed expectations, supporting keeping the case under review until margin trends stabilize.
Recent news
Q3 report released on 29 October showed revenue of SEK 2,500 M and adjusted EBITA of SEK 262 M, missing consensus. The stock fell sharply to around SEK 53.70 on margin pressure and weaker automotive volumes, while Medical Solutions delivered strong 9% organic growth.